全文获取类型
收费全文 | 6194篇 |
免费 | 398篇 |
国内免费 | 16篇 |
专业分类
耳鼻咽喉 | 175篇 |
儿科学 | 374篇 |
妇产科学 | 66篇 |
基础医学 | 657篇 |
口腔科学 | 81篇 |
临床医学 | 489篇 |
内科学 | 1408篇 |
皮肤病学 | 139篇 |
神经病学 | 478篇 |
特种医学 | 184篇 |
外科学 | 1072篇 |
综合类 | 58篇 |
一般理论 | 2篇 |
预防医学 | 468篇 |
眼科学 | 102篇 |
药学 | 381篇 |
中国医学 | 5篇 |
肿瘤学 | 469篇 |
出版年
2023年 | 32篇 |
2022年 | 58篇 |
2021年 | 203篇 |
2020年 | 119篇 |
2019年 | 171篇 |
2018年 | 229篇 |
2017年 | 173篇 |
2016年 | 178篇 |
2015年 | 207篇 |
2014年 | 302篇 |
2013年 | 342篇 |
2012年 | 482篇 |
2011年 | 490篇 |
2010年 | 251篇 |
2009年 | 217篇 |
2008年 | 391篇 |
2007年 | 379篇 |
2006年 | 340篇 |
2005年 | 288篇 |
2004年 | 274篇 |
2003年 | 277篇 |
2002年 | 212篇 |
2001年 | 76篇 |
2000年 | 69篇 |
1999年 | 70篇 |
1998年 | 49篇 |
1997年 | 47篇 |
1996年 | 49篇 |
1995年 | 34篇 |
1994年 | 26篇 |
1993年 | 23篇 |
1992年 | 35篇 |
1991年 | 31篇 |
1990年 | 33篇 |
1989年 | 28篇 |
1988年 | 38篇 |
1987年 | 27篇 |
1986年 | 32篇 |
1985年 | 31篇 |
1984年 | 19篇 |
1983年 | 25篇 |
1982年 | 24篇 |
1981年 | 23篇 |
1980年 | 16篇 |
1979年 | 18篇 |
1978年 | 14篇 |
1977年 | 18篇 |
1976年 | 14篇 |
1973年 | 16篇 |
1972年 | 18篇 |
排序方式: 共有6608条查询结果,搜索用时 609 毫秒
61.
Antoinette R Tan Xiaowei Yang Stephen M Hewitt Arlene Berman Erin R Lepper Alex Sparreboom Allyson L Parr William D Figg Catherine Chow Seth M Steinberg Stephen L Bacharach Millie Whatley Jorge A Carrasquillo Jaime S Brahim Seth A Ettenberg Stan Lipkowitz Sandra M Swain 《Journal of clinical oncology》2004,22(15):3080-3090
PURPOSE: To evaluate changes in epidermal growth factor receptor (EGFR) phosphorylation and its downstream signaling in tumor and surrogate tissue biopsies in patients with metastatic breast cancer treated with erlotinib, an EGFR tyrosine kinase inhibitor, and to assess relationships between biomarkers in tumor and normal tissues and between biomarkers and pharmacokinetics. PATIENTS AND METHODS: Eighteen patients were treated orally with 150 mg/d of erlotinib. Ki67, EGFR, phosphorylated EGFR (pEGFR), phosphorylated mitogen-activated protein kinase (pMAPK), and phosphorylated AKT (pAKT) in 15 paired tumor, skin, and buccal mucosa biopsies (at baseline and after 1 month of therapy) were examined by immunohistochemistry and analyzed quantitatively. Pharmacokinetic sampling was also obtained. RESULTS: The stratum corneum layer and Ki67 in keratinocytes of the epidermis in 15 paired skin biopsies significantly decreased after treatment (P = .0005 and P = .0003, respectively). No significant change in Ki67 was detected in 15 tumors, and no responses were observed. One was EGFR-positive and displayed heterogeneous expression of the receptor, and 14 were EGFR-negative. In the EGFR-positive tumor, pEGFR, pMAPK, and pAKT were reduced after treatment. Paradoxically, pEGFR was increased in EGFR-negative tumors post-treatment (P = .001). Although markers were reduced in surrogate and tumor tissues in the patient with EGFR-positive tumor, no apparent associations were observed in patients with EGFR-negative tumor. CONCLUSION: Erlotinib has inhibitory biologic effects on normal surrogate tissues and on an EGFR-positive tumor. The lack of reduced tumor proliferation may be attributed to the heterogeneous expression of receptor in the EGFR-positive patient and absence of target in this cohort of heavily pretreated patients. 相似文献
62.
Gerald E Hanks Thomas F Pajak Arthur Porter David Grignon Harmart Brereton Varagur Venkatesan Eric M Horwitz Colleen Lawton Seth A Rosenthal Howard M Sandler William U Shipley 《Journal of clinical oncology》2003,21(21):3972-3978
PURPOSE: Radiation Therapy Oncology Group (RTOG) Protocol 92-02 was a randomized trial testing long-term (LT) adjuvant androgen deprivation (AD) after initial AD with external-beam radiotherapy (RT) in patients with locally advanced prostate cancer (PC; T2c-4) and with prostate-specific antigen level less than 150 ng/mL. PATIENTS AND METHODS: Patients received a total of 4 months of goserelin and flutamide, 2 months before and 2 months during RT. A radiation dose of 65 to 70 Gy was given to the prostate and a dose of 44 to 50 Gy to the pelvic lymph nodes. Patients were randomly assigned to receive no additional therapy (short-term [ST]AD-RT) or 24 months of goserelin (LTAD-RT); 1,554 patients were entered onto the study. RESULTS: The LTAD-RT arm showed significant improvement in all efficacy end points except overall survival (OS; 80.0% v 78.5% at 5 years, P =.73), compared with the STAD-RT arm. In a subset of patients not part of the original study design, with tumors assigned Gleason scores of 8 to 10 by the contributing institutions, the LTAD-RT arm had significantly better OS (81.0% v 70.7%, P =.044). There was a small but significant increase in the frequency of late radiation grades 3, 4, and 5 gastrointestinal toxicity ascribed to the LTAD-RT arm (2.6% v 1.2% at 5 years, P =.037), the cause of which is not clear. CONCLUSION: The RTOG 92-02 trial supports the addition of LT adjuvant AD to STAD with RT for T2c-4 PC. In the exploratory subset analysis of patients with Gleason scores 8 to 10, LT adjuvant AD resulted in a survival advantage. 相似文献
63.
64.
Uterine thermal balloon therapy for the treatment of menorrhagia: the first 300 patients from a multi-centre study 总被引:6,自引:0,他引:6
Nazar N. Amso Consultant Seth A. Stabinsky Clinical Assistant Professor/Associate Medical Director †‡ Peter McFaul Consultant Bernard Blanc Professor †† Laura Pendley Manager ‡ Robert Neuwirth Professor/Chairman Emeritus § 《BJOG : an international journal of obstetrics and gynaecology》1998,105(5):517-523
65.
66.
Daniella Amital Leah Fostick Yehuda Sasson Seth Kindler Howard Amital Joseph Zohar 《European neuropsychopharmacology》2005,15(3):279-282
BACKGROUND: Several lines of evidence point to serotonergic abnormalities in patients with panic disorder (PD). Our goal was to further examine central serotonergic function in panic patients using autonomic and subjective responses to the postsynaptic serotonin 5-HT1D receptor agonist Sumatriptan. METHOD: Using a double-blind, randomized, placebo-controlled design, we assessed autonomic and subjective responses to oral Sumatriptan (100 mg) and placebo in 15 patients with PD, free of medication. Subjective responses were measured using the Hamilton Anxiety Rating Scale (HAM-A), National Institute of Mental Health Anxiety Scale (NIMHA), a modified version of the Panic Symptom Inventory (PI), Hamilton Depression Rating Scale (HAM-D), and Montgomery-Asberg Depression Rating Scale (MADRS). RESULTS: PD patients exhibited significantly enhanced autonomic and subjective responses following challenge with Sumatriptan. We observed an increased pulse rate and augmentation of various parameters measured on different anxiety scales. A constant inclination of aggravation of the measured parameters was detected during the hour post challenge. CONCLUSION: Oral administration of Sumatriptan, a 5-HT1D agonist, has been associated with an anxiogenic effect in PD patients. 相似文献
67.
68.
Polymorphisms in XPD exons 10 and 23 and bladder cancer risk. 总被引:3,自引:0,他引:3
Matthew B Schabath George L Delclos H Barton Grossman Yunfei Wang Seth P Lerner Robert M Chamberlain Margaret R Spitz Xifeng Wu 《Cancer epidemiology, biomarkers & prevention》2005,14(4):878-884
INTRODUCTION: The nucleotide excision repair gene, xeroderma pigmentosum complementation group D (XPD), has been hypothesized to have a role in cancer risk, but results from prior molecular epidemiologic studies and genotype-phenotype analyses are conflicting. MATERIALS AND METHODS: We examined the frequency of the XPD Asp312Asn polymorphism in exon 10 and the XPD Lys751Gln polymorphism in exon 23 in 505 incident bladder cancer cases and 486 healthy controls. RESULTS: Overall, the XPD exon 10 and 23 genotypes were not associated with bladder cancer risk, after adjusting for age, sex, ethnicity, and smoking status. A gender-specific role was evident that showed an increased risk for women, but not for men, associated with the variant genotypes for both exons. For example, when the exon 23 variant allele genotypes were combined (Lys/Gln + Gln/Gln), there was an increased bladder cancer risk in women [odds ratio (OR), 1.69; 95% confidence interval (95% CI), 1.12-2.58] but not in men (OR, 0.99; 95% CI, 0.79-1.24; P(interaction) = 0.041; OR, 1.62; 95% CI, 1.02-2.58). There was also a gene-smoking interaction that showed the variant alleles for either exon or the combination of both increase the risk of bladder cancer for light and heavy smokers. For exon 23 (P(interaction) = 0.057; OR, 1.21; 95% CI, 0.99-1.47), heavy smokers (> or = 20 pack-years) who carried the exon 23 variant allele genotypes had an OR of 4.13 (95% CI, 2.53-6.73), whereas heavy smokers with the wild-type genotypes were at lower risk (OR, 3.55; 95% CI, 2.19-5.75). Moderate smokers (1-19 pack-years) with the variant allele genotypes had an OR of 1.54 (95% CI, 0.94-2.53), whereas moderate smokers with the wild-type genotypes had an OR of 1.12 (95% CI, 0.63-1.98). CONCLUSIONS: Although we did not observe main effects associated with the XPD genotypes, these results do suggest the variant allele genotypes were associated with increased bladder cancer risk in women and smokers with statistically significant interactions in the exon 23 polymorphism. Although there is biological plausibility, these novel findings for gender and smoking should be interpreted with caution upon confirmation in larger studies. 相似文献
69.
Stephan Mielke Alex Sparreboom Seth M Steinberg Hans Gelderblom Clemens Unger Dirk Behringer Klaus Mross 《Clinical cancer research》2005,11(13):4843-4850
PURPOSE: The shortening of infusion time from 3 to 1 hour decreases the systemic exposure (area under the curve, AUC) of total and unbound paclitaxel but increases the AUC of its vehicle Cremophor EL, whereas the time above total paclitaxel concentrations of 0.05 micromol/L (T >0.05) remains almost constant. As both Cremophor EL and paclitaxel are neurotoxic, we evaluated their pharmacodynamic effects on the development of peripheral neuropathy as the most important nonhematologic toxicity. EXPERIMENTAL DESIGN: Patients with advanced cancer of different origin were randomized to receive a maximum of 12 weekly-given 1- or 3-hour infusions of 100 mg/m2 paclitaxel (Taxol). Twenty-four patients were assessable for both pharmacokinetics and peripheral neuropathy development evaluated by a clinical scoring system including sensory symptoms, strength, tendon reflexes, and vibratory sense. RESULTS: Patients with peripheral neuropathy development (n=14) received more weeks of therapy (P=0.056) and showed significantly higher T(>0.05) (P=0.022) and overall systemic drug exposures (weeks of therapy x AUC) for total paclitaxel (P=0.002) and unbound paclitaxel (P=0.003) than those without peripheral neuropathy. In Kaplan-Meier analyses, T(>0.05) > or = 10.6 hours (P=0.023), AUC of total paclitaxel > or = 4.7 microg/mL x hour (P = 0.047), and AUC of unbound paclitaxel > or = 0.375 microg/mL x hour (P = 0.095) were identified as being potential factors for peripheral neuropathy development. In a Cox regression analysis, only T(>0.05) > or = 10.6 hours remained as an independent risk factor (relative risk, 18.43; P = 0.036) after adjusting for prior vincamycin (relative risk, 11.28; P = 0.038). CONCLUSIONS: From the results obtained in this study, it is concluded that exposure to paclitaxel but not Cremophor EL is associated with peripheral neuropathy development. 相似文献
70.
Complement activation plays an important role in the pathogenesis of atypical hemolytic uremic syndrome. Eculizumab is a monoclonal antibody that blocks complement activity and has been approved for use in the treatment of atypical hemolytic uremic syndrome (HUS). Less well appreciated is the role of complement in Shiga toxin‐induced HUS (Shiga toxin producing Escherichia coli [STEC]‐HUS). To a limited extent, eculizumab has been used off label in patients with severe STEC‐HUS with neurological involvement. Through a systematic search of available databases, we identified 16 reports describing the use of eculizumab in STEC‐HUS (eight case reports/series, seven retrospective studies, and one prospective cohort study). All studies described its use in severe STEC‐HUS with neurological or multiorgan dysfunction; none were randomized or blinded. Four studies used the control groups. Although the overall quality of evidence is low, some published studies showed positive clinical improvement after treatment with eculizumab in severe STEC‐HUS with progressive neurological involvement. 相似文献